Larimar Therapeutics (LRMR) Cash from Financing Activities: 2013-2020
Historic Cash from Financing Activities for Larimar Therapeutics (LRMR) over the last 7 years, with Dec 2020 value amounting to $242,000.
- Larimar Therapeutics' Cash from Financing Activities fell 93.00% to $242,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $93.6 million, marking a year-over-year increase of 382.53%. This contributed to the annual value of $161.9 million for FY2024, which is 539510.00% up from last year.
- Per Larimar Therapeutics' latest filing, its Cash from Financing Activities stood at $242,000 for Q4 2020, which was up 279.26% from -$135,000 recorded in Q3 2020.
- Larimar Therapeutics' 5-year Cash from Financing Activities high stood at $83.9 million for Q2 2020, and its period low was -$756,000 during Q4 2016.
- In the last 3 years, Larimar Therapeutics' Cash from Financing Activities had a median value of $2.6 million in 2018 and averaged $15.0 million.
- Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 300.55% in 2016, then skyrocketed by 32,850.00% in 2019.
- Larimar Therapeutics' Cash from Financing Activities (Quarterly) stood at -$756,000 in 2016, then surged by 2,577.51% to $18.7 million in 2017, then plummeted by 90.62% to $1.8 million in 2018, then spiked by 96.64% to $3.5 million in 2019, then plummeted by 93.00% to $242,000 in 2020.
- Its last three reported values are $242,000 in Q4 2020, -$135,000 for Q3 2020, and $83.9 million during Q2 2020.